FDA Approves New Influenza Vaccine Manufactured with Novel Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Approves New Influenza Vaccine Manufactured with Novel Technology


ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA has approved Protein Sciences’s FluBlok, a seasonal influenza vaccine made with novel technology. FluBlok uses recombinant DNA and a modified baculovirus (a virus that infects insects) to produce a safe and effective human influenza vaccine. FDA approved FluBlok for people 18–49 years old.

“This approval represents a technological advance in the manufacturing of an influenza vaccine,” said Karen Midthun, director of FDA’s Center for Biologics Evaluation and Research, in a Jan. 16, 2013, FDA press release. “The new technology offers the potential for faster start-up of the vaccine manufacturing process in the event of a pandemic because it is not dependent on an egg supply or on availability of the influenza virus.”

According to a press release, Flublok is an influenza vaccine made without the use of live influenza virus and it’s an egg-free influenza vaccine. In addition, it contains highly purified properties without preservatives (thimerosal), antibiotics, or adjuvants; and three times the active ingredient of that in traditional influenza vaccines.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here